Atoltivimab + Odesivimab + Maftivimab

Category: Antiviral

Atoltivimab + Odesivimab + Maftivimab Overview

Atoltivimab/maftivimab/odesivimab, developed as REGN-EB3 and sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus).[2] It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.[2] The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are al...

Read more Atoltivimab + Odesivimab + Maftivimab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Atoltivimab + Odesivimab + Maftivimab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Atoltivimab + Odesivimab + Maftivimab
  • Solution: 16.7mg/1ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (1 result)

  • INMAZEB Atoltivimab + Odesivimab + Maftivimab

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 May 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA